OS after BCMA-directed CAR T relapse stratified by disease characteristics. (A) OS curve, stratified by triple-class refractory status (defined as refractory to ≥1 immunomodulatory drug, ≥1 proteasome inhibitor, and ≥1 anti-CD38 monoclonal antibody). (B) OS curve, stratified by penta-drug refractory status (defined as refractory to ≥2 immunomodulatory drugs, ≥2 proteasome inhibitors, and ≥1 anti-CD38 mAb).